Soleno Therapeutics Faces Class Action Over Troubling Drug Launch and Investor Lawsuit

Overview of Soleno Therapeutics' Legal Troubles

In a recent development that has captured the attention of investors and healthcare professionals alike, Soleno Therapeutics, Inc. (NASDAQ: SLNO) is now facing a class action lawsuit aimed at representing shareholders who bought its common stock between March 26, 2025, and November 4, 2025. This lawsuit comes on the heels of a disheartening report released on November 5, 2025, regarding the company’s new drug, DCCR (trademarked as VYKAT™ XR), which is positioned as a treatment for hyperphagia, a condition deemed as the most debilitating aspect of Prader-Willi Syndrome (PWS).

The Background

Jeffy, an industry analyst, highlighted that hyperphagia is notably recognized for significantly impairing quality of life for affected individuals, which adds to the stakes surrounding the efficacy and safety of VYKAT™ XR. Prader-Willi Syndrome itself is a rare genetic disorder marked by developmental, physical, and behavioral disabilities, intensifying concerns regarding the administration of treatments.

Following the release of the aforementioned report by Soleno, which delineated disappointing metrics regarding VYKAT™ XR’s launch, there was a rapid and drastic sell-off in company shares, leading to a staggering 26% drop in value on the same day. This response from the market has drawn scrutiny from investors, triggering legal actions to determine if shareholders were misled about the drug’s prospects and safety.

Details of the Lawsuit

The pivotal aspects of the lawsuit revolve around the claims that Soleno made regarding the drug’s safety and its market prospects. Throughout its promotion of VYKAT™ XR, the company allegedly claimed that the launch had been pleasingly successful, stating it exceeded expectations. However, details emerged that suggested Soleno had sensationalized the effectiveness and downplayed potential safety issues associated with DCCR, particularly regarding excess fluid retention observed in clinical trials.

The complaint accuses Soleno executives of concealing significant evidence of safety risks, thereby potentially jeopardizing the health of patients who might use the drug. Additionally, the allegations highlight that the commercial viability of VYKAT™ XR was grossly misrepresented in disclosures to investors.

Investors first began to see signs of trouble on August 15, 2025, when Scorpion Capital, an activist short-seller, openly challenged Soleno's statements and raised critical alarms about VYKAT™ XR's safety profile. The report noted alarming trends, including reports of children experiencing hospitalizations due to potential heart failure soon after initiating treatment with the drug. These revelations led to increased skepticism concerning the drug’s viability in the market.

The Market Reaction

As concerns grew, the reaction from investors was swift; since August 14, 2025, the stock price for Soleno saw a near 40% decrease by November 5, 2025. On November 4, during the quarterly earnings call, the company acknowledged launching hurdles, stating there had been a disruption attributed to adverse reports affecting start forms and discontinuations linked to non-serious side effects.

The Investigation Continues

Hagens Berman, the firm leading the class action, is now investigating if Soleno misrepresented its claims regarding VYKAT™ XR. Hagens Berman's partner, Reed Kathrein, has stated, "We are looking closely at whether Soleno misled investors about VYKAT™ XR’s commercial viability and safety implications." The implications of the results could have broader consequences for the firm and stakeholders involved.

Additionally, Hagens Berman is encouraging any investors who believe they have incurred losses due to the situation at Soleno to come forward. The firm is also open to whistleblowers who may possess non-public information that could assist their investigation, outlining that they could be eligible for rewards if such evidence leads to a successful recovery.

Conclusion

This unfolding situation at Soleno Therapeutics serves as a crucial reminder of the complexities involved in drug development and the market's demand for transparency from pharmaceutical companies. As the litigation progresses, all eyes will be on the outcomes of this class action lawsuit, assessing not just the fate of Soleno but broader industry standards regarding investor communications and patient safety. Stakeholders are encouraged to stay updated as developments continue to unfold in what may become a high-profile case in the pharmaceutical realm.